As TrialSite recently covered, evidence is mounting that Ivermectin is effective as both a prophylactic to prevent COVID-19 infections and a potent treatment. Now, two new studies in pre-print add to the Ivermectin picture. Of course, ideally, these studies shall be peer reviewed and published in a known medical journal. In the first study, researchers in India did a matched case-control analysis and found that Ivermectin profoundly lowers the chance of catching the SARS-CoV-2 virus. The subjects for the study were some of the most at risk, health care workers at the All India Institute Of Medical Sciences, New Delhi (AIIMS). It was a hospital-based matched case-control study conducted from September to October. Factors including profession, sex, age, and date of diagnosis were matched for 186 case-control pairs.
AIIMS Stems from Indian Independence
Dramatically, a two-dose Ivermectin was associated with a 73% reduction in COVID-19 infections over a month period. This study used a dose of 300 μg/kg given twice. The institution behind this work, AIIMS, is a result of India’s goal of creating a nation “imbued” with scientific culture. Just after independence, Jawaharlal Nehru...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).